[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
March 1, 2000

Thrombolytic Therapy for Ischemic StrokeFrom Clinical Trials to Clinical Practice

Author Affiliations

Author Affiliation: Neurological Institute, New York, NY.

JAMA. 2000;283(9):1189-1191. doi:10.1001/jama.283.9.1189

Intravenous tissue-type plasminogen activator (tPA) for ischemic stroke has broken a major therapeutic barrier, and much more progress is certain to follow. Steadily accumulating data continue to justify current guidelines for use of tPA in stroke,1 and demonstrate that low complication rates can be achieved with proper use of this therapy. Renewed interest in hyperacute treatment of stroke may breathe new life into neuroprotective agents and acute interventional and surgical therapies, alone or with tPA.

First Page Preview View Large
First page PDF preview
First page PDF preview
×